LungLifeAI Logo

Videos & Presentations

Our Purpose:
To be a driving force in the early detection of lung cancer.

June 25, 2024

Lung Life AI's CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic, Lung LB®

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI’s journey to date and […]
• View Media
April 8, 2024

Presentation: Audited results for the year ended 31 December 2023

Paul Pagano and David Anderson give a presentation on LungLife's results for the year ended 31 December 2023, via the Investor Meet Company platform.
• View Media
August 9, 2023

Presentation: Half-year report for the six months ended 30 June 2023

Paul Pagano and David Anderson give a presentation on LungLife's Interim results for the six months ended 30 June 2023, via the Investor Meet Company platform.
• View Media
August 8, 2023

Q&A with Lunglife AI's CEO, Paul Pagano

In this interview, Paul Pagano CEO of Lunglife AI #LLAI takes Vox through today’s ‘in line’ H1’23 results and the next steps wrt commercialising its ground-breaking early stage lung cancer blood test.
• View Media
February 22, 2023

PRESENTATION: FULL YEAR RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022

Watch Paul Pagano and David Anderson give a presentation on LungLife's Annual Results for the year ended 31 December 2022, via the Investor Meet Company platform.  
• View Media
September 29, 2022

Presentation: Interim results for the six months ended 30 June 2022

Paul Pagano and David Anderson give a presentation on LungLife's Interim results for the six months ended 30 June 2022, via the Investor Meet Company platform.
• View Media
April 1, 2022

Presentation: Full Year Results for the year ended 31 December 2021

Paul Pagano and David Anderson give a presentation on LungLife's Annual Results for the year ended 31 December 2021, via the Investor Meet Company platform.
• View Media
January 27, 2022

Edison Open House interview with CEO, Paul Pagano

LungLife AI: Edison Open House Healthcare 2022
• View Media
September 9, 2021

Half Year Results to 30 June, 2021

Paul Pagano and David Anderson talk with Justin Waite of VOX Markets. Paul Pagano and David Anderson's presentation to the investor community on the results to the period.
• View Media
July 9, 2021

Introduction to LungLife AI, Inc post Admission

Paul Pagano talks with Paul Hill of VOX Markets following the Company's IPO on 8 July, 2021.
• View Media

Media inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down